Literature DB >> 33167690

Etiological classification and treatment strategies for secondary bile duct dilatation.

Yunfu Lv1, Ning Liu1, Hongfei Wu1, Zhuori Li1.   

Abstract

Secondary intra- and extrahepatic bile duct dilatation is a very common condition that can be caused by several diseases. However, it has been rarely discussed in the specialized literature. Moreover, no distinct etiology can be determined in some cases, which hampers the diagnosis and treatment. Here, we discuss the etiological classification and treatment strategies of secondary intra- and extrahepatic bile duct dilatation based on an extensive literature review, as well as our experimental research and clinical experience. The etiology of secondary intra- and extrahepatic bile duct dilatation can be classified in different ways. From a clinicopathological perspective, it can be classified into obstruction-, lesion-, and compression-induced dilatation. Treatment varies depending on the cause. For example, endoscopic dilation or stenting is used for biliary strictures, laparoscopic choledochectomy for stone removal, and resection for cholangiocarcinoma.

Entities:  

Keywords:  Bile duct dilatation; diagnosis; etiological classification; intra- and extrahepatic; secondary; treatment

Mesh:

Substances:

Year:  2020        PMID: 33167690      PMCID: PMC7876649          DOI: 10.1177/1535370220966767

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  26 in total

1.  Biliary tract obstruction secondary to malignant lymphoma: experience at a referral center.

Authors:  Bülent Odemiş; Erkan Parlak; Omer Başar; Osman Yüksel; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

Review 2.  Sphincter of Oddi dysfunction: how is it diagnosed? How is it classified? How do we treat it medically, endoscopically, and surgically?

Authors:  Attila Nakeeb
Journal:  J Gastrointest Surg       Date:  2013-07-17       Impact factor: 3.452

3.  A comparative study of the diagnostic accuracy of the medical image three-dimensional visualization system, MRCP, CT and US in hepatolithiasis.

Authors:  Gang Li; Chi-Hua Fang; Ying-Fang Fan; Tian-Chong Wu; Shi-Zhen Zhong
Journal:  Hepatogastroenterology       Date:  2014-10

Review 4.  Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: an Update on MR Imaging Findings with Recent Developments.

Authors:  Jelena Djokić Kovač; Marc-André Weber
Journal:  J Gastrointestin Liver Dis       Date:  2016-12       Impact factor: 2.008

5.  Liver transplantation for intrahepatic cholangiocarcinoma.

Authors:  David D Lee; Kristopher P Croome; Kaitlyn R Musto; Jose Melendez; Ghassan Tranesh; Raouf Nakhleh; C Burcin Taner; Justin H Nguyen; Tushar Patel; Denise M Harnois
Journal:  Liver Transpl       Date:  2018-05       Impact factor: 5.799

Review 6.  [Diagnosis of common bile duct stones in symptomatic gallstone disease].

Authors:  V B Kristiansen; J Rosenberg; H Kehlet
Journal:  Ugeskr Laeger       Date:  2000-07-31

7.  Common bile duct stones: analysis of the videolaparoscopic surgical treatment.

Authors:  Marco Aurelio Santo; Carlos Eduardo Domene; Daniel Riccioppo; Lian Barreira; Flavio Roberto Takeda; Henrique Walter Pinotti
Journal:  Arq Gastroenterol       Date:  2012 Jan-Mar

8.  Inferior pancreaticoduodenal artery false aneurysm: a rare cause of gastrointestinal bleeding diagnosed by three-dimensional computed tomography.

Authors:  M C Colak; H Kocaturk; E Bayram; L Karaca
Journal:  Singapore Med J       Date:  2009-10       Impact factor: 1.858

9.  Malignant biliary strictures in patients with a normal bilirubin and/or normal liver enzymes.

Authors:  Sarah C Thomasset; David Saunders; Adele Holland; Ashley R Dennison; Giuseppe Garcea
Journal:  HPB (Oxford)       Date:  2015-08-07       Impact factor: 3.647

10.  Spontaneous remission of obstructive jaundice in rats: Selection of experimental models.

Authors:  Yunfu Lv; Jie Yue; Xiaoguang Gong; Xiaoyu Han; Hongfei Wu; Jie Deng; Yejuan Li
Journal:  Exp Ther Med       Date:  2018-05-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.